ArticleCureus2025
Early Treatment With Curative Dose Low-Molecular-Weight Heparin (LMWH) Versus Plasmapheresis in Severe Acute Pancreatitis in Intensive Care: A Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute pancreatitis (SAP) of hyperlipidemic origin is a serious condition that may require advanced therapeutic interventions (e.g., intravenous fluids, analgesics, insulin infusion, plasmapheresis, nutritional support, and endoscopic/surgical management). While plasmapheresis is used to eliminate circulating triglycerides and inflammatory mediators, low-molecular-weight heparins (LMWH) may offer an alternative through thrombo-inflammatory modulation.
objectiveTo compare the efficacy and safety of early therapeutic-dose LMWH versus plasmapheresis in the management of SAP.
methodsThis prospective, observational, single-center study included 100 patients with hypertriglyceridemia-induced SAP. Patients were divided into two groups: 50 received therapeutic-dose LMWH, and 50 underwent plasmapheresis. Primary outcomes included necrosis rate, complication frequency, ICU stay, and mortality. Adverse events related to both interventions were recorded.
resultsLMWH was associated with a lower rate of pancreatic necrosis (8% vs. 44%, p=0.0003), fewer overall complications (10% vs. 60%, p=0.0001), and a shorter ICU stay (6.4 vs. 12.7 days, p<0.001). Mortality was lower in the LMWH group (2% vs. 14%, p=0.03). Procedure-related adverse events were less frequent with LMWH than with plasmapheresis.
conclusionIn this single-center observational study, therapeutic-dose LMWH was associated with improved clinical outcomes and fewer adverse events compared to plasmapheresis. These findings suggest LMWH may be a safe and effective option for managing hypertriglyceridemia-induced SAP, though randomized controlled trials are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.